← Leaderboards
Bethany Westlund
Cambria Biosciences, Llc
$1,543,095
Attributed
$1,543,095
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $588.7K · FY2006–07$1M$750K$500K$250K$0
'06
'07
Funding mix
By agency
NIH$1,543,095 · 3
By mechanism
R43$795,238 · 2
R44$747,857 · 1
Top collaborators
No co-investigators on record.
Most similar at Cambria Biosciences, Llc
Same institution · by research overlap
- Ann E Sluder$1,272,481
- Donald R. Kirsch$805,284
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeHigh Throughput TechnologyTechnology /Technique DevelopmentProtein Structure FunctionAnthelminticsGenetic ScreeningHost Organism InteractionSecretionCaenorhabditis ElegansDrug Screening /EvaluationCellular AssayCellsCell LineCellular StressAnimalsAgingDopaminergic NeuronDesignCytotoxicBrainAnimal ModelDoseComputersComplex
Grant awards (4)
COMPOUNDS ACTIVATING DJ-1 AS THERAPEUTICS FOR PARKINSON'S DISEASE$588,696
R43 · FY2007 · NS · contact PI
Compounds Targeting Nematode Secretion as Novel Anti-filarial Drugs$206,542
R43 · FY2006 · AI · contact PI
A C. ELEGANS SCREEN FOR NOVEL ANTINEMATODE DRUGS$272,671
R44 · FY2003 · AI
A C. ELEGANS SCREEN FOR NOVEL ANTINEMATODE DRUGS$475,186
R44 · FY2002 · AI